Mycobacterial 70kD heat-shock protein is an effective subunit vaccine against bovine paratuberculosis

Abstract

Paratuberculosis is a chronic granulomatous inflammation of the small intestine of cattle and other ruminants, caused by infection with Mycobacterium avium ssp. paratuberculosis (MAP). The disease can be found in ruminant herds worldwide, causing substantial economic losses at farm level due to premature culling and production losses.In previous studies, it has been shown that immune responses to recombinant MAP Hsp70 proteins were predominantly cell mediated. As protective immunity to the intracellular mycobacterial pathogens is thought to be cell-mediated in origin, we have studied the use of a recombinant MAP Hsp70 as a subunit vaccine in cattle experimentally infected with MAP.The results of the current study demonstrate that recombinant MAP Hsp70 can be successfully used as a subunit vaccine against bovine paratuberculosis, significantly reducing shedding of bacteria in feces during the first 2 years following experimental infection.

Heat-shock protein 70 expression in the seminal plasma of patients with chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome

“…It also has a role in protein homeostasis, thus maintaining vital cellular functions during periods of cellular distress, including bacterial infections. 16,17 The specific role of HSP70 in stress tolerance has been elucidated in a number of studies. [18][19][20][21][22] In this study, we evaluated HSP70 expression in the seminal plasma of patients with chronic bacterial prostatitis, CP/CPPS and healthy controls, and focused on the variety in the expression of HSP70, which has different roles in the pathogenesis of chronic bacterial prostatitis and CP/CPPS.…”

Bovine paratuberculosis: recent advances in vaccine development

“…Several Th1 antigens have been identified by genomic and proteomic analysis: the antigen 85 complex proteins (A, B and C) and superoxide dismutase (Shin et al 2005); Hsp65 and Hsp70 (Koets et al 1999); lipoprotein LprG ( (Rigden et al 2006); PPE family proteins MAP1518 and MAP3184 (Nagata et al 2005). Only few of these have been tested in cattle, the target species, namely: the antigen 85 complex proteins together with superoxide dismutase and heat shock protein 70 (Koets et al 2006;Kathaperumal et al 2008). …”

“…However, whether short-term experimental infection models could predict efficacy in clinical disease prevention is a question that remains to be answered. Experimental challenge of calves with MAP leads to a reproducible infection (Koets et al 2006;Hines et al 2007;van Roermund et al 2007;Stewart et al 2007;Stabel et al 2009). The first peak of faecal shedding of MAP starts at 3 months after challenge in a high proportion of animals, and after 5 months the frequency of positive faecal culture samples declines and for the remainder of the follow-up period animals intermittently shed bacteria in the faeces.…”

Quantification of Mycobacterium avium subsp. paratuberculosis from the tissues of challenged mice using SYBR Green real time PCR assay for the assessment of vaccine efficacy

“…Prophylactic vaccination has been employed as a control measure, even though not completely effective in preventing disease (Cocito et al, 1994). Vaccination with heat inactivated whole cell based vaccines is widely in practice in Australia (Gudair TM ) and USA (Mycopar TM ) (Reddacliff et al, 2006;Koets et al, 2006). The protective efficacy of these vaccines has been tested in sheep and cattle (Munoz et al, 2005;Reddacliff et al, 2006).…”

“…The protective efficacy of these vaccines has been tested in sheep and cattle (Munoz et al, 2005;Reddacliff et al, 2006). However, challenge studies in calves to assess the protective efficacy of the vaccines are cumbersome, expensive and are limited by the long incubation period of MAP for 2-3 years (Koets et al, 2006). BALB/c Mice are suggested to be valuable tools for the preclinical testing of JD vaccine candidates (Hines et al, 2007;Rosseels and Huygen, 2008) and most suitable for MAP infection studies (Hines et al, 2007;Veazey et al, 1995).…”